PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för cenicriviroc. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

23 hits

Bibliografisk träff 2020-07-21

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.

Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, Aithal GP, Kowdley KV, Seyedkazemi S, Fischer L, Loomba R, Abdelmalek MF, Tacke F.

Hepatology · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/hep.31108

Bibliografisk träff 2020-03-15

Erratum: Cenicriviroc ameliorates the severity of graft-versus host disease through inhibition of CCR5 in a rat model of liver transplantation.

Li M, Lu C, Zhu H, Kang X, Wang F, Shao L, Lu X, Chen W, Xia X.

Am J Transl Res · published erratum; correction; journal article

Bibliografisk träff 2019-12-24

Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.

Anstee QM, Neuschwander-Tetri BA, Wong VW, Abdelmalek MF, Younossi ZM, Yuan J, Pecoraro ML, Seyedkazemi S, Fischer L, Bedossa P, Goodman Z, Alkhouri N, Tacke F, Sanyal A.

Contemp Clin Trials · clinical trial protocol; research support, non-u.s. gov't; journal article · DOI 10.1016/j.cct.2019.105922

Bibliografisk träff 2019-11-20

The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid.

Dilly Penchala S, Alagaratnam J, Challenger E, Amara A, Else L, Winston A, Khoo S.

Biomed Chromatogr · journal article · DOI 10.1002/bmc.4711

Bibliografisk träff 2019-11-13

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.

Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM.

Contemp Clin Trials · clinical trial protocol; research support, non-u.s. gov't; journal article · DOI 10.1016/j.cct.2019.105889

Bibliografisk träff 2019-10-29

CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.

Blackard JT, Kong L, Rouster SD, Karns R, Horn PS, Kottilil S, Shata MT, Sherman KE.

PLoS One · research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0224523

Bibliografisk träff 2019-10-24

Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study.

Wang Z, Park H, Bae EJ.

Korean J Physiol Pharmacol · research-article; journal article · DOI 10.4196/kjpp.2019.23.6.459

Bibliografisk träff 2019-08-01

Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy.

Bowler S, Siriwardhana C, Mitchell BI, D'Antoni ML, Ogata-Arakaki D, Souza S, Yee R, Gangcuangco LMA, Chow DC, Ndhlovu LC, Shikuma C.

HIV Res Clin Pract · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1080/25787489.2020.1719319

Bibliografisk träff 2019-06-15

Cenicriviroc ameliorates the severity of graft-versus-host disease through inhibition of CCR5 in a rat model of liver transplantation.

Li M, Lu C, Zhu H, Kang X, Wang F, Shao L, Lu X, Chen W, Xia X.

Am J Transl Res · research-article; journal article

Bibliografisk träff 2019-05-01

Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade.

Sherman KE, Abdel-Hameed E, Rouster SD, Shata MTM, Blackard JT, Safaie P, Kroner B, Preiss L, Horn PS, Kottilil S.

Clin Infect Dis · clinical trial, phase ii; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1093/cid/ciy807

Bibliografisk träff 2019-02-12

Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice.

Ambade A, Lowe P, Kodys K, Catalano D, Gyongyosi B, Cho Y, Iracheta-Vellve A, Adejumo A, Saha B, Calenda C, Mehta J, Lefebvre E, Vig P, Szabo G.

Hepatology · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/hep.30249

Bibliografisk träff 2018-12-01

Role of cenicriviroc in the management of nonalcoholic fatty liver disease.

Neokosmidis G, Tziomalos K.

World J Gastroenterol · editorial · DOI 10.3748/wjg.v24.i48.5415

Bibliografisk träff 2018-08-08

Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.

D'Antoni ML, Mitchell BI, McCurdy S, Byron MM, Ogata-Arakaki D, Chow D, Mehta NN, Boisvert WA, Lefebvre E, Shikuma CM, Ndhlovu LC, Baumer Y.

J Leukoc Biol · comparative study; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/jlb.5a0817-328rrr

Bibliografisk träff 2018-08-08

APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.

Covino DA, Purificato C, Catapano L, Galluzzo CM, Gauzzi MC, Vella S, Lefebvre E, Seyedkazemi S, Andreotti M, Fantuzzi L.

Front Immunol · research support, non-u.s. gov't; research-article; journal article · DOI 10.3389/fimmu.2018.01839

Bibliografisk träff 2018-03-21

The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmdmdx-4Cv) mice.

Liang F, Giordano C, Shang D, Li Q, Petrof BJ.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0194421

Bibliografisk träff 2018-02-22

Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.

Tacke F.

Expert Opin Investig Drugs · review; journal article · DOI 10.1080/13543784.2018.1442436

Bibliografisk träff 2018-02-19

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.

Krenkel O, Puengel T, Govaere O, Abdallah AT, Mossanen JC, Kohlhepp M, Liepelt A, Lefebvre E, Luedde T, Hellerbrand C, Weiskirchen R, Longerich T, Costa IG, Anstee QM, Trautwein C, Tacke F.

Hepatology · research support, non-u.s. gov't; journal article · DOI 10.1002/hep.29544

Bibliografisk träff 2016-05-12

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment.

Lefebvre E, Gottwald M, Lasseter K, Chang W, Willett M, Smith PF, Somasunderam A, Utay NS.

Clin Transl Sci · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1111/cts.12397

Bibliografisk träff 2015-11-02

Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.

Kuwata T, Enomoto I, Baba M, Matsushita S.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.02285-15

Bibliografisk träff 2015-08-06

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0134904

Bibliografisk träff 2014-11-02

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc.

Kramer V, Hassounah S, Colby-Germinario S, Mesplède T, Lefebvre E, Wainberg M.

J Int AIDS Soc · abstract; journal article · DOI 10.7448/ias.17.4.19531

Bibliografisk träff 2010-08-01

Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection.

Klibanov OM, Williams SH, Iler CA.

Curr Opin Investig Drugs · journal article

Bibliografisk träff 2005-11-01

TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.

Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1128/aac.49.11.4584-4591.2005